Presentations by Program

Search by Program

Discovery of ETX2514, a novel, rationally designed inhibitor of Class A, C and D β–lactamases, for the treatment of Gram-negative infections

Thomas Durand-Reville, ACS 2017

ETX2514 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo,

Alita Miller, ECCMID 2017

Pathogen-directed strategies at Entasis Therapeutics

Alita Miller, SDRI 2017

Antibiotic Resistance: A real and present danger in our hospitals

Ruben Tommasi, Gordon Research Conference 2017

Improving our understanding of porin permeability in Gram-negative bacteria

Ruben Tommasi, PEW-NIAID Workshop 2017

Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broad-spectrum activity against Class A, C and D enzymes

Alita Miller, Superbugs & Superdrugs USA 2016

Microbiological Cure Rates and Antimicrobial Susceptibility of Neisseria gonorrhoeaeto ETX0914 (AZD0914) in a Phase II Treatment Trial for Urogenital Gonorrhea

Stephanie N. Taylor, MD; LSU-Crescent Care Sexual Health Center, ID Week 2016

Global Surveillance of the Activity of Sulbactam combined with the Novel β-lactamase InhibitorETX2514 against Clinical Isolates of Acinetobacter baumannii from 2014

Kenneth Lawrence, ID Week 2016

Human PK and Dose Projection of ETX2514 / Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii

John O’Donnell, ID Week 2016

Sulbactam Combined with the Novel β–lactamase Inhibitor ETX2514 for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections

Alita Miller, ID Week 2016